🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great start to World GU Conference with an interactive poster session. Hannah Dzimitrowicz McManus discussing high uptake of combined therapy for mHSPC in IRONMAN Registry @loreleimucci

Fantastic insights from ⁦Alicia Morgans, MD, MPH⁩ ⁦Rana McKay, MD, FASCO⁩ ⁦Dana Rathkopf⁩ ⁦Shilpa Gupta⁩ in the women leaders in GU session ⁦World GU Conference⁩

Backstage World GU Conference what is happening???

Thrilled to have @DCockerellMD join the DukeRaleigh site of the DCI Center for Prostate and Urologic Cancers, With #SundarRamalingham already there to show him the ropes, should be smooth sailing.

ANNOUNCING: The 2nd World GU Conference! This 2-Day CME/CE meeting will take place August 21-23, 2025 in vibrant Nashville, Tennessee where over 50 esteemed faculty members will share the latest GU updates. Watch our #WorldGU24 summary! worldguconference.com #WorldGU2025

Great opening session at #GU25. Talapro2 data demonstrating clear and significant survival benefit to adding Tala to Enza in all comers with mCRPC. Let the data speak for itself! Congrats Neeraj Agarwal, MD, FASCO and colleagues

Come see ⁦Hannah Dzimitrowicz McManus⁩ present our latest #IRONMAN data demonstrating the prognostic significance of PSA nadir <0.2 in mHSPC.

Check out the data from PSMAfore biomarker analysis: Huge prognostic significance in baseline and 6-week on treatment ctDNA levels and outcomes. Adds to PSA 50 response as well. Could guide future management in this earlier disease setting. ⁦⁦⁦Duke Cancer⁩ #GU25

Hannah McManus presents update on IRONMAN registry data at #GU25. Hannah Dzimitrowicz McManus Phil Kantoff Duke Cancer

First large-scale study reporting OS with Lu-PSMA-617 (Pluvicto) in clinical setting. Similar OS regardless of age, race/ethnicity, number or type of metastasis. Listen for my take on why real world data is so important for our older patients. Median age in study = 69 yo. #GU25

Great time spent here ASCO #GU25 with our growing DCI Center for Prostate & Urologic Cancers team tonight. Maybe this should be our first cross post to Bluesky? Andrew Armstrong Dan George Michael Harrison Tian Zhang, MD, MHS Rhonda Bitting

Super excited that Joe Park and Jordan Infield will soon join our Duke Cancer GU medical oncology faculty. Here they share highlights from bladder cancer research at #GU25

Don't miss our current editorial in ASCO Daily News on treatment options and areas of research in 2nd line and beyond mRCC. Great job Matt Labriola and Patrick O'Shea. Duke Cancer #GU25 #kidneycancer

Duke Urologic Oncology fellow Alireza Ghoreifi, MD rocked the bladder cancer poster walk last night, reporting on impact of blue light stratification of NMIBC Duke Cancer

And we have several more active trials in #kidneycancer and #bladdercancer

Grateful that a member of our GUrus Patient Advisory Council braved #ASCO2025 to "peek behind the curtain" and see what clinical investigators & industry professionals are doing for people surviving #ProstateCancer #KidneyCancer & #bladdercancer Duke Cancer @Chelseahandler